PUBLISHER: Grand View Research | PRODUCT CODE: 1813859
PUBLISHER: Grand View Research | PRODUCT CODE: 1813859
The global lactate monitoring devices market size was estimated at USD 150.73 million in 2024 and is projected to reach USD 325.88 million by 2033, growing at a CAGR of 9.05% from 2025 to 2033. The increasing awareness of the benefits of monitoring lactate in sports & healthcare, the rise in the need for point-of-care tests, and the growing adoption of remote patient monitoring & telemedicine are significant factors contributing to market growth.
In addition, expanding use in surgical and post-operative monitoring is further anticipated to propel market growth. Moreover, an increase in the adoption of home-based healthcare and the aging population are some other factors fueling market growth further.
Lactate monitoring has become a core diagnostic tool in managing critically ill patients, particularly in the context of sepsis, trauma, and organ dysfunction. Elevated lactate levels are widely recognized as an early biochemical marker of tissue hypoperfusion and cellular oxygen debt, even before visible clinical deterioration occurs. This allows clinicians to identify patients at risk of rapid decline and initiate timely interventions aimed at stabilizing hemodynamics and restoring perfusion. In November 2024, according to Sepsis Alliance, sepsis remained the leading cause of death in U.S. hospitals, accounting for 35% of in-hospital deaths.
Moreover, lactate monitoring is also critical in managing a broader range of conditions where impaired tissue perfusion is a concern. In trauma, cardiac arrest, and complex post-surgical scenarios, elevated lactate levels often signal underlying circulatory compromise before vital signs shift. Clinicians rely on this metric to assess the severity of shock, guide escalation of care, and support decisions around surgical intervention, transfusion, or advanced life support.
Furthermore, lactate monitoring is increasingly being adopted during and after major surgeries, particularly cardiac, abdominal, and trauma procedures, as elevated lactate levels can indicate insufficient tissue perfusion or complications such as internal bleeding. Intraoperative monitoring enables anesthesiologists and surgeons to make timely clinical decisions, while post-operative monitoring supports early identification of adverse outcomes, ultimately improving recovery rates.
For instance, a study titled "Real-Time Biomarkers of Liver Graft Quality in Hypothermic Oxygenated Machine Perfusion," published in the Journal of Clinical Medicine in January 2025, explored the use of perfusate lactate concentration during dual hypothermic oxygenated machine perfusion (dHOPE) as a real-time, accessible biomarker to assess liver graft quality pre-transplantation. The study demonstrated that lactate levels measured after 120 minutes of dHOPE reliably predicted early allograft dysfunction (EAD) and correlated with post-transplant complications and length of hospital stay. This approach offers a cost-effective and reproducible alternative to complex biomarker assays, advocating for the broader adoption of lactate monitoring across transplant centers to improve organ utilization and patient outcomes.
Global Lactate Monitoring Devices Market Report Segmentation
This report forecasts, revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global lactate monitoring devices market report based on product, application, end use, and region.